Leerink Partnrs Has Optimistic Outlook of MIRM Q3 Earnings

Key Points

• Leerink Partners has raised its Q3 2025 EPS estimate for Mirum Pharmaceuticals from (0.18) to (0.12), indicating an improved outlook for the company's financial performance.
• HC Wainwright and TD Cowen both upgraded their ratings on the stock, with price targets now reaching up to $81.00, reflecting strong investor confidence.
• Insider selling activity has been notable, with significant stock disposals by CEO Christopher Peetz and SVP Jolanda Howe, which raises questions about the company's internal confidence amidst positive analyst ratings.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) - Analysts at Leerink Partnrs raised their Q3 2025 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research report issued on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($0.12) per share for the quarter, up from their prior estimate of ($0.18). The consensus estimate for Mirum Pharmaceuticals' current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals' Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.70) EPS.

Several other research analysts have also weighed in on MIRM. HC Wainwright increased their target price on Mirum Pharmaceuticals from $73.00 to $80.00 and gave the stock a "buy" rating in a research report on Thursday, August 7th. TD Cowen raised Mirum Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, September 25th. Wall Street Zen raised Mirum Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 26th. Raymond James Financial reiterated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 7th. Finally, Morgan Stanley lifted their price target on Mirum Pharmaceuticals from $75.00 to $81.00 and gave the stock an "overweight" rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $79.70.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $74.42 on Friday. Mirum Pharmaceuticals has a 52-week low of $36.88 and a 52-week high of $78.54. The stock's fifty day simple moving average is $72.31 and its 200-day simple moving average is $55.49. The company has a quick ratio of 2.97, a current ratio of 3.13 and a debt-to-equity ratio of 1.21. The stock has a market capitalization of $3.74 billion, a price-to-earnings ratio of -61.50 and a beta of 0.81.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative return on equity of 24.76% and a negative net margin of 13.65%.The business had revenue of $127.79 million for the quarter, compared to analysts' expectations of $107.91 million. During the same quarter last year, the firm earned ($0.52) earnings per share. The business's revenue was up 64.1% on a year-over-year basis.

Insiders Place Their Bets

In related news, SVP Jolanda Howe sold 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $58.00, for a total transaction of $580,000.00. Following the sale, the senior vice president owned 2,426 shares of the company's stock, valued at $140,708. The trade was a 80.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Christopher Peetz sold 40,000 shares of the business's stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $62.00, for a total value of $2,480,000.00. Following the sale, the chief executive officer directly owned 138,641 shares in the company, valued at approximately $8,595,742. The trade was a 22.39% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 116,578 shares of company stock worth $7,262,824. 14.36% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC raised its holdings in Mirum Pharmaceuticals by 30.8% during the third quarter. CWM LLC now owns 683 shares of the company's stock worth $50,000 after purchasing an additional 161 shares in the last quarter. Voya Investment Management LLC raised its holdings in Mirum Pharmaceuticals by 18.1% during the third quarter. Voya Investment Management LLC now owns 78,897 shares of the company's stock worth $5,784,000 after purchasing an additional 12,106 shares in the last quarter. Osaic Holdings Inc. raised its holdings in Mirum Pharmaceuticals by 46.5% during the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company's stock worth $56,000 after purchasing an additional 351 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Mirum Pharmaceuticals by 389.6% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $244,000 after purchasing an additional 3,810 shares in the last quarter. Finally, Soleus Capital Management L.P. bought a new stake in Mirum Pharmaceuticals during the second quarter worth approximately $15,201,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.